腔内灌注贝伐单抗治疗恶性胸腹腔积液的研究进展

Research progress of intrapleural or intraperitoneal bevacizumab in treating of malignant pleural and peritoneal effusion

恶性胸腹腔积液是晚期恶性肿瘤最严重并发症之一。对于胸腹腔积液全身化疗效果多不理想,常采用局部治疗。血管内皮生长因子可以促进恶性胸腹腔积液的生成,贝伐单抗是一种抗血管内皮生长因子的单克隆抗体,腔内灌注贝伐单抗在治疗恶性胸腹腔积液方面具有一定的疗效。

Malignant pleural and peritoneal effusion is one of the most serious complications of advanced malignancy.At present,the effect of systemic chemotherapy is not ideal for malignant pleural and peritoneal effusion,and local treatment is often used.In recent years,the generation of malignant pleural and peritoneal effusion was found to be directly related to increased secretion of the vascular endothelial growth factor(VEGF).Bevacizumab is a humanized monoclonal antibody against human VEGF.Studies have showed that intrapleural and intraperitoneal bevacizumab was an effective way in the treatment of malignant pleural and peritoneal effusion.